Zhongyuan Union Cell & Gene Engineering Corp Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Zhongyuan Union Cell & Gene Engineering Corp Ltd with three other
companies in this sector in China:
Beijing SL Pharmaceutical Co Ltd
sales of 1.01 billion Chinese Renmimbi [US$151.04 million]
of which 98%
was Pharmaceuticals Industry),
Boya Bio pharmaceutical Group Co Ltd
(946.57 million Chinese Renmimbi [US$141.58 million]
of which 56%
was Blood Plasma), and
Tianjin Ringpu Bio-Technology Co Ltd
(969.68 million Chinese Renmimbi [US$145.04 million]
of which 63%
was Veterinary Biological Products).
During the year ended December of 2016, sales at
Zhongyuan Union Cell & Gene Engineering Corp Ltd were 835.64 million Chinese Renmimbi (US$124.99 million).
increase of 18.2%
versus 2015, when the company's sales were 706.86 million Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Zhongyuan Union Cell & Gene Engineering Corp Ltd
(and since 2011, sales have increased a total of 239%).
Sales of Detection Reagent saw an increase
24.4% in 2016, from
249.98 million Chinese Renmimbi to 310.87 million Chinese Renmimbi.
Not all segments of Zhongyuan Union Cell & Gene Engineering Corp Ltd experienced an increase in sales in 2016:
sales of Cosmetics Manufacturing fell 85.8% to 1.02 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Zhongyuan Union Cell & Gene Engineering Corp Ltd also experienced decreases in sales in
Other Operations (down 44.9% to 14.51 million Chinese Renmimbi)